Latest Commercialisation News

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.

Green Critical Minerals has commissioned its first VHD Graphite production module and secured $7 million to drive commercialisation, while its McIntosh Project delivers robust economic metrics.

Hazer Group has forged a strategic alliance with engineering giant KBR to fast-track commercial deployment of its methane pyrolysis technology, supported by a $10.7 million capital raise and promising project developments in Japan.

Elevate Uranium Ltd has made significant strides in its uranium exploration and development efforts, with its U-pgrade pilot plant nearing shipment and promising drilling results expanding mineralisation at key Namibian projects.

Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.

Atomo Diagnostics has successfully placed $260,000 of the shortfall from its recent Share Purchase Plan, issuing over 14 million shares and options to sophisticated investors. This capital injection strengthens the company’s working capital position as it advances its rapid diagnostic test business.

InteliCare Holdings announces CEO Daniel Pilbrow’s resignation effective October 2025, with Non-Executive Director Tim Chapman stepping in as interim executive director during the leadership transition.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

Amaero Ltd reports solid June quarter revenue and signs a pivotal five-year exclusive supply agreement with Velo3D, underpinning its growth outlook and updated EBITDA guidance for FY2027.

RareX Limited has successfully raised A$2 million through a share placement at a premium, positioning itself to advance exploration and development across key rare earths projects in Australia and Kenya.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.